RUBICONRubicon Research Limited
Pharma · Drug Manufacturers - General · NSE · as of 2026-07-20 (delayed ~30 min in market hours)
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on RUBICON — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why buy
- • Revenue growth: 43.5% YoY
- • Profit growth: 96.6% YoY
- • ROE: 27.0%
- • RSI: 68
- • Price vs EMA21: above
- • Price vs SMA50: above
Bull case
- • Revenue growth: 43.5% YoY
- • Profit growth: 96.6% YoY
- • ROE: 27.0%
- • RSI: 68
Bear case
- • Valuation vs sector: P/E 92.6 vs sector 38.6
- • Dividend yield: 0.00%
- • MACD: bearish
- • Volume trend: 0.5x baseline
Key risks
- • Valuation vs sector: P/E 92.6 vs sector 38.6
- • Dividend yield: 0.00%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹71.13). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.